Inclusion on the list of medicines reimbursed by National Insurance (packages of 5, 10 and 30 tablets) and approved for use by hospitals (packages of 5, 10, 30 and 100 tablets).
-
Clinical Benefit
Substantial
The actual benefit of XARELTO 10 mg tablets is substantial.
Clinical Added Value
minor
XARELTO 10 mg tablets provides a minor improvement in actual benefit (IAB IV) in terms of efficacy compared with LOVENOX (enoxaparin) for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.
Listen
